ERB-196

ERB-196
Clinical data
Other names	WAY-202196
Identifiers
	IUPAC name 3-(3-Fluoro-4-hydroxyphenyl)-7-hydroxynaphthalene-1-carbonitrile;
CAS Number	550997-55-2;
PubChem CID	6102691;
DrugBank	DB06875;
ChemSpider	4810213;
ChEMBL	ChEMBL192154;
CompTox Dashboard (EPA)	DTXSID70422018 ;
Chemical and physical data
Formula	C17H10FNO2
Molar mass	279.27 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1(=CC2=C(C(=C1)C#N)C=C(C=C2)O)C1=CC(=C(C=C1)O)F;
	InChI InChI=1S/C17H10FNO2/c18-16-7-10(2-4-17(16)21)12-5-11-1-3-14(20)8-15(11)13(6-12)9-19/h1-8,20-21H; Key:NSSOSHDCWCMNDM-UHFFFAOYSA-N;

ERB-196, also known as WAY-202196, is a synthetic nonsteroidal estrogen that acts as a highly selective agonist of the ERβ.[1][2][3][4][5][6] It possesses 78-fold selectivity for the ERβ over the ERα.[1] The drug was under development by Wyeth for the treatment of inflammation and sepsis starting in 2004 but development was discontinued by 2011.[2][7]

References

R. E. Hubbard (2006). Structure-based Drug Discovery: An Overview. Royal Society of Chemistry. pp. 241–. ISBN 978-0-85404-351-4.
https://adisinsight.springer.com/drugs/800021229%5B%5D
Estrogens—Advances in Research and Application: 2013 Edition: ScholarlyBrief. ScholarlyEditions. 21 June 2013. pp. 52–. ISBN 978-1-4816-8771-3.
Eckhard Ottow; Hilmar Weinmann (8 September 2008). Nuclear Receptors as Drug Targets. John Wiley & Sons. pp. 66–. ISBN 978-3-527-62330-3.
Mewshaw RE, Edsall RJ, Yang C, Manas ES, Xu ZB, Henderson RA, Keith JC, Harris HA (2005). "ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity". J. Med. Chem. 48 (12): 3953–79. doi:10.1021/jm058173s. PMID 15943471.
Cristofaro PA, Opal SM, Palardy JE, Parejo NA, Jhung J, Keith JC, Harris HA (2006). "WAY-202196, a selective estrogen receptor-beta agonist, protects against death in experimental septic shock". Crit. Care Med. 34 (8): 2188–93. doi:10.1097/01.CCM.0000227173.13497.56. PMID 16755255.
Jean-Louis Vincent (8 December 2007). Yearbook of Intensive Care and Emergency Medicine 2007. Springer Science & Business Media. pp. 891–. ISBN 978-3-540-49433-1.

External links

ERB-196 - AdisInsight

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[Hubbard2006-1] R. E. Hubbard (2006). Structure-based Drug Discovery: An Overview. Royal Society of Chemistry. pp. 241–. ISBN 978-0-85404-351-4.

[AdisInsight-2] ttps://adisinsight.springer.com/drugs/800021229%5B%5D

[ScholarlyEditions2013-3] Estrogens—Advances in Research and Application: 2013 Edition: ScholarlyBrief. ScholarlyEditions. 21 June 2013. pp. 52–. ISBN 978-1-4816-8771-3.

[OttowWeinmann2008-4] Eckhard Ottow; Hilmar Weinmann (8 September 2008). Nuclear Receptors as Drug Targets. John Wiley & Sons. pp. 66–. ISBN 978-3-527-62330-3.

[pmid15943471-5] Mewshaw RE, Edsall RJ, Yang C, Manas ES, Xu ZB, Henderson RA, Keith JC, Harris HA (2005). "ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity". J. Med. Chem. 48 (12): 3953–79. doi:10.1021/jm058173s. PMID 15943471.

[pmid16755255-6] Cristofaro PA, Opal SM, Palardy JE, Parejo NA, Jhung J, Keith JC, Harris HA (2006). "WAY-202196, a selective estrogen receptor-beta agonist, protects against death in experimental septic shock". Crit. Care Med. 34 (8): 2188–93. doi:10.1097/01.CCM.0000227173.13497.56. PMID 16755255.

[Vincent2007-7] Jean-Louis Vincent (8 December 2007). Yearbook of Intensive Care and Emergency Medicine 2007. Springer Science & Business Media. pp. 891–. ISBN 978-3-540-49433-1.

ERB-196

See also

References

External links